Skip to Content

Tygacil Approval History

Tygacil (tigecycline) is a glycylcycline antibacterial indicated for the treatment of complicated skin and skin structure infections, complicated intra-abdominal infections and community-acquired bacterial pneumonia in adults.

Development History and FDA Approval Process for Tygacil

Mar 24, 2009Approval FDA Approves New Indication for Wyeth's Tygacil (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia
May 29, 2008Wyeth Receives Approvable Letter from FDA for Tygacil for theTreatment of Patients with Community-Acquired Pneumonia
Oct 24, 2007FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
Jul  6, 2007Wyeth to File for FDA Approval of Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
Jun 15, 2005Approval Tygacil Wyeth Pharmaceuticals - Treatment for Complicated Skin and Intra-abdominal Infections
Jan 28, 2005FDA Grants Tygacil (Tigecycline) NDA Priority Review Status
Dec 15, 2004Wyeth Seeks Global Regulatory Approval of Tygacil (Tigecycline) for Injection

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.